Armata Pharmaceuticals, Inc.

Phase 3 AI-extracted

AP-SA02

complicated bacteremia caused by Staphylococcus aureus

Countdown

177days

Phase 3 readout · ~ Dec 31, 2026 estimated

What's at stake Phase 3 trial results for AP-SA02 in complicated bacteremia caused by Staphylococcus aureus are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 8-K verified 13h ago

““Our top priority in 2026 is advancing Armata’s lead Staphylococcus aureus (“ S. aureus ”) therapeutic phage candidate, AP-SA02, into a Phase 3 superiority study in complicated S. aureus bacteremia (“SAB”),””

Add to calendar Post on X Reddit

Provenance